|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been ... |
|
|
Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer have actionable biomarkers within this pat... |
|